Biosense Webster launches the Optrell Mapping Catheter with TRUEref technology for mapping of complex cardiac arrhythmias.
Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech announced the U.S. launch of the Optrell Mapping Catheter with TRUEref Technology powered by the CARTO 3 System
The Optrell Mapping Catheter is a high-density diagnostic catheter, with small electrodes arranged in a fixed array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.
Cardiac arrhythmias are a growing epidemic. AFib (atrial fibrillation) is the most common type of cardiac arrhythmia and impacts nearly 40 million people worldwide, with up to 6 million of these individuals living in the U.S. AFib is a progressive disease, and if left untreated can get worse over time or lead to other serious complications like heart disease or stroke. Catheter ablation is a safe and effective procedure to restore the heart’s incorrect electrical signals, which causes an abnormal heart rhythm.
This new catheter includes 48 electrodes symmetrically distributed across and along six splines and combines with the CARTO 3 System to deliver intelligent insights and high-resolution directional mapping. Additionally, the Optrell Mapping Catheter has tight electrode spacing and small electrodes, which produce higher signal resolution, resulting in enhanced maps of the heart.With these high-definition maps, clinicians have a better understanding of where the arrhythmia is occurring and can develop a more effective ablation strategy.
“The Optrell Mapping Catheter has a fixed electrode array structure that provides greater diagnostic insight, which allows physicians to quickly and effectively identify ablation targets,” said Pasquale Santangeli, M.D., Ph.D., Cardiovascular Medicine, Cleveland Clinic Main Campus. “This catheter and the Local Conduction Vectors give me the confidence to quickly and effectively detect ablation lesion gaps and the arrhythmia substrate, even in the most complex cases, including persistent AFib, redo AFib ablation, atrial tachycardia, and ventricular tachycardia.”
The Optrell Mapping Catheter is powered by the CARTO 3 System, which offers Local Conduction Vectors that display the real-time direction and speed of the electrical impulses traveling through the heart. With these Local Conduction Vectors, clinicians gain enhanced understanding of complex circuits and mechanisms and can confidently detect gaps in ablation lesions. Together, these technologies can help clinicians quickly identify areas that need ablation and apply more effective therapy in a shorter time.
The Optrell Mapping Catheter received 510(k) approval on 18 March 2022.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins